

Ning Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9432725/publications.pdf>

Version: 2024-02-01

37
papers

9,854
citations

687363
13
h-index

395702
33
g-index

37
all docs

37
docs citations

37
times ranked

16383
citing authors

#	ARTICLE	IF	CITATIONS
1	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 844-847.	3.8	4,615
2	Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1094-1099.	3.8	2,925
3	ISTH interim guidance on recognition and management of coagulopathy in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1023-1026.	3.8	1,513
4	Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 1107-1110.	2.1	359
5	Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 580-586.	2.1	127
6	Coagulation Dysfunction. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1223-1229.	2.5	50
7	Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2428-2430.	3.8	29
8	Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1520-1521.	3.8	27
9	Response to 'Lupus anticoagulant is frequent in patients with Covid-19' (JTH-2020-00483). <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2065-2066.	3.8	25
10	Laboratory haemostasis monitoring in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2058-2060.	3.8	25
11	Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients. <i>Thrombosis Research</i> , 2018, 172, 9-13.	1.7	23
12	Type and dose of heparin in Covid-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2063-2064.	3.8	19
13	DOACs and 'newer' hemophilia therapies in COVID-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1795-1796.	3.8	17
14	Characteristics of emergency patients with markedly elevated D-dimer levels. <i>Scientific Reports</i> , 2020, 10, 7784.	3.3	14
15	Time course of soluble P-selectin and von Willebrand factor levels in trauma patients: a prospective observational study. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2013, 21, 70.	2.6	13
16	The Value of Thromboelastography for Bleeding Risk Prediction in Hematologic Diseases. <i>American Journal of the Medical Sciences</i> , 2016, 352, 502-506.	1.1	12
17	The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 223-229.	1.2	10
18	PROS1 IVS10+5G>A mutation causes hereditary protein S deficiency in a Chinese patient with pulmonary embolism and venous thromboembolism. <i>Thrombosis Research</i> , 2019, 174, 1-4.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Concurrent hematoma and venous thrombosis in a patient with autoimmune acquired factor XIII deficiency. International Journal of Laboratory Hematology, 2020, 42, e4-e6.	1.3	5
20	Effects of hemolysis and lipemia interference on kaolin-activated thromboelastography, and comparison with conventional coagulation tests. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 98-103.	1.2	4
21	Significantly Prolonged Prothrombin Time and Activated Partial Thromboplastin Time with no Bleeding Tendency: A Patient with Lupus Anticoagulantâ€“Hypoprothrombinemia Syndrome Positive for Immunoglobulin M Anti-Phosphatidylserine/Prothrombin complex Antibodies. Seminars in Thrombosis and Hemostasis, 2020, 46, 507-511.	2.7	4
22	Two cases of von Willebrand disease type 3 in consanguineous Chinese families. Molecular Genetics & Genomic Medicine, 2020, 8, e1075.	1.2	4
23	Response to 'Pulmonary thrombosis in 2019â€“CoV pneumonia?'. Journal of Thrombosis and Haemostasis, 2020, 18, 1513-1514.	3.8	4
24	Plasma Antiphospholipid Antibodies Effects on Activated Partial Thromboplastin Time Assays. American Journal of the Medical Sciences, 2017, 354, 22-26.	1.1	3
25	Determining the cutoff value of the APTT mixing test for factor VIII inhibitor. Clinical Chemistry and Laboratory Medicine, 2019, 57, e88-e90.	2.3	3
26	Deep intronic F8 c.5999-27A>G variant causes exon 19 skipping and leads to moderate hemophilia A. Blood Coagulation and Fibrinolysis, 2020, 31, 476-480.	1.0	3
27	Response to â€“Inaccurate conclusions by Tang and colleaguesâ€™. Journal of Thrombosis and Haemostasis, 2020, 18, 1798-1798.	3.8	3
28	Significantly prolonged <scp>PT</scp> and <scp>APTT</scp> could indicate a wide spectrum of clinical manifestations in three patients with plasma cell disorders. International Journal of Laboratory Hematology, 2019, 41, e23-e26.	1.3	2
29	Congenital fibrinogen disorder caused by digenic mutations of the FGA and FGB genes. Hematology, 2020, 25, 145-148.	1.5	2
30	Predictive value of coagulation factor XIII on bleeding risk in ischemic stroke patients treated with intravenous thrombolysis. Annals of Palliative Medicine, 2021, 10, 7579-7586.	1.2	2
31	A Case of Parturient with Hereditary Thrombotic Thrombocytopenic Purpura: Case Report of a Novel Variant. Seminars in Thrombosis and Hemostasis, 2021, , .	2.7	2
32	Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. American Journal of the Medical Sciences, 2018, 355, 350-356.	1.1	1
33	Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report. BMC Medical Genetics, 2018, 19, 163.	2.1	1
34	<i>F8</i> IVS9+5G>A mutation causes moderate haemophilia A. Haemophilia, 2019, 25, e132-e135.	2.1	1
35	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. , 2020, 18, 844.		1
36	Different manifestations of patients with inhibitors against prothrombin and thrombin. Journal of Thrombosis and Thrombolysis, 2020, 49, 164-167.	2.1	0

#	ARTICLE	IF	CITATIONS
37	Normal activated partial thromboplastin time in Chinese patients with mild hemophilia B. Hematology, 2020, 25, 484-488.	1.5	0